Skip to content

Citius Oncology, Inc. CTOR Prepaid & Other Current

Prepaid & Other Current at other companies

Delcath Systems logo
Delcath SystemsDCTH
$7M+59.9%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$12.93M-18.7%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$9.52M-31.7%
Immunome logo
ImmunomeIMNM
$11.62M+100%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$20.44M+81.2%
Gilead Sciences logo
Gilead SciencesGILD
$4.34B+53.5%

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherPrepaidExpenseCurrent.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s prepaid & other current?
Citius Oncology, Inc. (CTOR) reported prepaid & other current of $221.11K in Q1 2026.
How has Citius Oncology, Inc.'s prepaid & other current changed year-over-year?
Citius Oncology, Inc.'s prepaid & other current decreased by 91.8% year-over-year, from $2.7M to $221.11K.
What is the long-term trend for Citius Oncology, Inc.'s prepaid & other current?
Over 2 years (2023 to 2025), Citius Oncology, Inc.'s prepaid & other current has grown at a -58.5% compound annual growth rate (CAGR), from $7.73M to $1.33M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.